Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 8/20 | 0.33 |
| ▸ | CA9 | Q16790 | 8/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459411 | 1.00 | GAA (0.38) | GAANR4A2KDM4EMAPTCA12 | |
| SCHEMBL3458675 | 0.96 | NR4A2 (0.36) | GAANR4A2KDM4EMAPTCA12 | |
| SCHEMBL3458674 | 0.96 | NR4A2 (0.36) | GAANR4A2KDM4EMAPTCA12 | |
| SCHEMBL6341328 | 0.92 | NR4A2 (0.38) | NR4A2CA12CA9F2CA2 | |
| SCHEMBL6614933 | 0.85 | MAPT (0.40) | GAAKDM4EMAPTCA12CA9 | |
| SCHEMBL5204894 | 0.79 | NR4A2 (0.37) | GAANR4A2MAPTCA12CA9 | |
| SCHEMBL5205301 | 0.79 | GABRA1 (0.39) | GAAKDM4EMAPT | |
| SCHEMBL10529566 | 0.75 | HSD17B3 (0.38) | NR4A2MAPTCA12CA9CA2 | |
| SCHEMBL6349353 | 0.75 | KDM4E (0.38) | KDM4EMAPTCTSL | |
| SCHEMBL24376093 | 0.75 | CA12 (0.36) | GAAKDM4EMAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3747881-B1 | NITROGEN-CONTAINING BENZOHETEROCYCLE COMPOUND COMPRISING CARBOXYLIC ACID GROUP, PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | Wuxi Life Fountain Biotech Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-3988098-A1 | HETEROCYCLO ALKYL COMPOUNDS USED AS CCR2/CCR5 ANTAGONIST | Shenzhen Lingfang Biotech Co., Ltd (CN) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020207263-A1 | BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2019149089-A1 | NITROGEN-CONTAINING BENZOHETEROCYCLE COMPOUND COMPRISING CARBOXYLIC ACID GROUP, PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-14 | — | — | US | disclosed |
| US-8741943-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2206702-A1 | Bicyclic compound, production and use thereof | Tobira Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7371772-B2 | Bicyclic compound, production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-13 | — | — | US | disclosed |
| EP-1889839-A1 | Bicyclic compound, production and use as HIV inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20040259876-A1 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1423376-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014105-A9 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003014105-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259876-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | GAA 4856/4885NR4A2 289/4885KDM4E 2986/4885 |
| US-20090030032-A1 | Bicyclic Compound, Production and Use Thereof | CCR5, CCR1, CCR2 | GAA 4845/4885NR4A2 265/4885KDM4E 2916/4885 |
| US-20160008326-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | GAA 4847/4885NR4A2 262/4885KDM4E 2868/4885 |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | CCR2, CCR5, CCRL2 | GAA 4290/4885NR4A2 469/4885KDM4E 4505/4885 |
| US-20190038604-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | GAA 4845/4885NR4A2 265/4885KDM4E 2916/4885 |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | GAA 532/4885NR4A2 2069/4885KDM4E 1986/4885 |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | GAA 4845/4885NR4A2 265/4885KDM4E 2916/4885 |
| US-20080161287-A1 | Bicyclic compound, production and use thereof | CCR5, CCR1, CCR2 | GAA 4845/4885NR4A2 265/4885KDM4E 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.